Newsletter | July 16, 2021

07.16.21 -- Choose The Right FDA Program To Expedite Your Rare Oncology Trial

Dermatology: The Changing Landscape Of Psoriasis Treatment

Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more than half of treated patients now able to achieve essentially complete clearing of their disease. Learn more about these therapies as well as new topical and oral therapies that are emerging.

5 Key Takeaways: Drug And Device Development Secrets In The World Of Medical Aesthetics

New treatment options for medical aesthetic indications are in record-high demand, fueled by growing awareness of the effects of physiological and environmental aging and the influence of lifestyle on skin health. Read this article to learn five of the most important takeaways for creating a competitive, differentiated aesthetic development program.

Adaptive Trial Designs In Early Oncology: Minimizing Risk And Accelerating Timelines

With the emergence of personalized medicine, a shift in how early-phase oncology trials are conducted is taking place, including a growing number of Phase 1 trials reporting preliminary response rates. This article addresses clinical trials in personalized medicine and explores the expanding role of adaptive trial designs in Phase 1 and Phase 2 oncology studies.

Choose The Right FDA Program To Expedite Your Rare Oncology Trial

Rare cancers pose challenges to drug development and represent a significant unmet need in oncology. Faced with limited treatment options, researchers, clinicians, and patients may be seeking approaches to accelerate the development and approval of novel therapies. Learn what regulatory programs are available to expedite treatments for rare disorders and serious diseases.

Tumor-Agnostic Treatments: A Game Changer For Rare Oncology Trials

As our understanding of the molecular characteristics of tumors has improved, there has been a tremendous leap forward — not only in targeted therapies but also in the development of tumor- or tissue-agnostic treatments. Now, with precision or personalized medicine, treatments can be targeted to a subgroup of patients rather than relying on a one-drug-fits-all model.